Lyell Immunopharma (LYEL) EBIT Margin (2020 - 2026)
Lyell Immunopharma (LYEL) reported EBIT Margin of 2213050.0% for Q1 2026, down 139352143.0% on a YoY basis from N/an in Q1 2025, and down 4.03% sequentially from 2127400.0% in Q4 2025.
Lyell Immunopharma (LYEL) EBIT Margin (2020 - 2026) Analysis & Trends
Lyell Immunopharma (LYEL) has 7 years of EBIT Margin data on file, last reported at 2213050.0% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin fell 139352143.0% year-over-year to 2213050.0%; the trailing twelve-month figure through Mar 2026 stood at 826767.74% (down 27208005.0% YoY), and the FY2025 full-year result was 748344.44%, down 16022149.0% from the prior year.
- EBIT Margin slipped to 2213050.0% in Q1 2026, from 2127400.0% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 30.55% in Q4 2022 to a low of 2214566.67% in Q3 2022.
- A 5-year average of 793232.29% and a median of 396369.23% in 2024 frame the typical range for EBIT Margin.
- Across the five-year window, EBIT Margin slumped 221278224 bps in 2022 and soared 197841067 bps in 2023, its largest moves.
- Tracing LYEL's EBIT Margin over 5 years: stood at 30.55% in 2022, then sank by 1498065 bps to 457753.85% in 2023, then slumped by 299 bps to 1828609.09% in 2024, then dropped by 16 bps to 2127400.0% in 2025, then slipped by 4 bps to 2213050.0% in 2026.
- Business Quant data shows LYEL's EBIT Margin at 2213050.0% in Q1 2026, 2127400.0% in Q4 2025, and 248353.33% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Lyell Immunopharma | 276.08 Mn | 276.08 Mn | - | -2,213,050.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,213,050.00% |
| Dec 31, 2025 | -2,127,400.00% |
| Sep 30, 2025 | -248,353.33% |
| Jun 30, 2025 | -589,250.00% |
| Mar 31, 2025 | -819,528.57% |
| Dec 31, 2024 | -1,828,609.09% |
| Sep 30, 2024 | -148,544.12% |
| Jun 30, 2024 | -396,369.23% |
| Mar 31, 2024 | -1,852,500.00% |
| Dec 31, 2023 | -457,753.85% |
| Sep 30, 2023 | -236,156.00% |
| Jun 30, 2023 | -244,092.59% |
| Mar 31, 2023 | -96,240.00% |
| Dec 31, 2022 | -30.55% |
| Sep 30, 2022 | -2,214,566.67% |
| Jun 30, 2022 | -104.25% |
| Mar 31, 2022 | -12,400.72% |
| Dec 31, 2021 | -1,684.55% |
| Sep 30, 2021 | -1,784.43% |
| Jun 30, 2021 | -2,386.11% |